Lauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 5,578 shares of the business’s stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total transaction of $146,199.38. Following the completion of the transaction, the senior vice president now owns 59,564 shares in the company, valued at $1,561,172.44. This represents a 8.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $25.97 on Friday. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $29.95. The firm has a 50-day simple moving average of $25.53 and a 200 day simple moving average of $23.32. The company has a market cap of $1.20 billion, a PE ratio of -12.79 and a beta of 0.56.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of PCRX. Alyeska Investment Group L.P. bought a new stake in shares of Pacira BioSciences during the 1st quarter valued at about $32,506,000. Point72 Asset Management L.P. bought a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $20,266,000. American Century Companies Inc. grew its position in shares of Pacira BioSciences by 392.2% during the 1st quarter. American Century Companies Inc. now owns 667,423 shares of the company’s stock valued at $16,585,000 after buying an additional 531,831 shares during the last quarter. Nuveen LLC bought a new stake in shares of Pacira BioSciences during the 1st quarter valued at about $12,884,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $8,558,000. Institutional investors own 99.73% of the company’s stock.

Analyst Ratings Changes

PCRX has been the subject of several research analyst reports. Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 9th. HC Wainwright boosted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, April 8th. Finally, Wall Street Zen raised shares of Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.